Articles published by GSK plc
![](https://mms.businesswire.com/media/20240726127513/en/2146668/5/GSK_Logo_Full_Colour_RGB.jpg)
![](https://mms.businesswire.com/media/20240702966375/en/2146668/5/GSK_Logo_Full_Colour_RGB.jpg)
![](https://mms.businesswire.com/media/20240606055012/en/2153317/22/AREXVY_Logo.jpg)
![](https://mms.businesswire.com/media/20240602370374/en/2146668/5/GSK_Logo_Full_Colour_RGB.jpg)
![](https://mms.businesswire.com/media/20240531991907/en/2146668/5/GSK_Logo_Full_Colour_RGB.jpg)
![](https://mms.businesswire.com/media/20240315640367/en/2069057/5/GSK_Logo_Full_Colour_RGB.jpg)
![](https://mms.businesswire.com/media/20240306698092/en/2057325/5/GSK_Logo.jpg)
![](https://mms.businesswire.com/media/20240131961986/en/2016625/5/GSK_Logo.jpg)
![](https://mms.businesswire.com/media/20231212489783/en/1966800/5/GSK_Logo_Full_Colour_RGB.jpg)
GSK Awards $1M in COiMMUNITY Initiative Grants to Support Adult Immunization and Health Equity
December 12, 2023
From GSK plc
Via Business Wire
Tickers
GSK
![](https://mms.businesswire.com/media/20231110216675/en/1942056/5/GSK_Logo_Full_Colour_RGB.jpg)
![](https://mms.businesswire.com/media/20231024909863/en/1924300/5/GSK_Logo.jpg)
New Data for AREXVY, GSK’s RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease
October 25, 2023
From GSK plc
Via Business Wire
Tickers
GSK
![](https://mms.businesswire.com/media/20230915284606/en/1891420/5/GSK_Logo_Full_Colour_RGB.jpg)
Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia
September 15, 2023
From GSK plc
Via Business Wire
Tickers
GSK
![](https://mms.businesswire.com/media/20230901805289/en/1880497/22/7046681_006_SidelineRSV_SocialCard_fa1.jpg)
GSK and Earvin “Magic” Johnson to Host Community Awareness Events about Older Adult Risk for RSV at YMCA Locations
September 05, 2023
From GSK plc
Via Business Wire
Tickers
GSK
![](https://mms.businesswire.com/media/20230817156317/en/1869303/22/AREXVY_Carton.jpg)
GSK Announces AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Is Now Available at All Major US Retail Pharmacies
August 17, 2023
From GSK plc
Via Business Wire
Tickers
GSK
![](https://mms.businesswire.com/media/20230731510497/en/1854889/5/GSK_Logo_Full_Colour_RGB.jpg)
![](https://mms.businesswire.com/media/20230712628446/en/1840682/5/GSK_Logo.jpg)
![](https://mms.businesswire.com/media/20230621184675/en/1825591/5/AREXVY_Logo.jpg)
![](https://mms.businesswire.com/media/20230620554754/en/1823893/5/AREXVY_Logo.jpg)
![](https://mms.businesswire.com/media/20230616166110/en/1821472/5/Lifetime_Logo%28R%29_Rose-White.jpg)
![](https://mms.businesswire.com/media/20230530005694/en/1806300/5/MicrosoftTeams-image_%2828%29.jpg)
GSK Announces the COiMMUNITY Initiative to Help Achieve Higher Adult Vaccination Rates in the US
June 01, 2023
From GSK plc
Via Business Wire
Tickers
GSK
![](https://mms.businesswire.com/media/20230503005829/en/1782764/22/AREXVY_Product_Image_Example.jpg)
US FDA Approves GSK’s AREXVY, the World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
May 03, 2023
From GSK plc
Via Business Wire
Tickers
GSK
![](https://mms.businesswire.com/media/20230314005817/en/1737265/5/GSK_Logo_Full_Colour_RGB.jpg)
GSK and Earvin “Magic” Johnson Partner to Raise Awareness of Risk of RSV in Older Adults
March 14, 2023
From GSK plc
Via Business Wire
Tickers
GSK
![](https://mms.businesswire.com/media/20221211005056/en/1661405/5/GSK_Logo_Full_Colour_RGB.jpg)
New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients
December 11, 2022
From GSK plc
Via Business Wire
Tickers
GSK
![](https://mms.businesswire.com/media/20220808005462/en/1537976/5/www.vaccinetrack.com_%282%29.jpg)
![](https://mms.businesswire.com/media/20220727005841/en/1526441/5/GSK_logo_2022.svg.jpg)
GSK Announces US FDA Approval of Benlysta (Belimumab) for Pediatric Patients With Active Lupus Nephritis
July 27, 2022
From GSK plc
Via Business Wire
Tickers
GSK
![](https://mms.businesswire.com/media/20220711005842/en/1509927/5/GSK_Logo_Full_Colour_RGB.jpg)
![](https://mms.businesswire.com/media/20220628006164/en/1499973/5/GSK_Logo_Full_Colour_RGB.jpg)
GSK Selects Target the Future Grant Recipient in Innovation Challenge Supporting Multiple Myeloma Community
June 29, 2022
From GSK plc
Via Business Wire
Tickers
GSK
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.